Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome

Mohammad Altermanini; Mhd Baraa Habib; Dania Alkhiyami; Khaled Ali; Mohamed Salah Abdelghani; Tahseen Hamamyh; Ahmad Elyas; Mawahib Elhassan

doi:10.1016/j.heliyon.2023.e18716

Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome

Heliyon. 2023 Jul 26;9(8):e18716. doi: 10.1016/j.heliyon.2023.e18716. eCollection 2023 Aug.

Authors

Mohammad Altermanini¹, Mhd Baraa Habib¹, Dania Alkhiyami², Khaled Ali³, Mohamed Salah Abdelghani⁴, Tahseen Hamamyh⁴, Ahmad Elyas⁴, Mawahib Elhassan⁴

Affiliations

¹ Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
² Hamad Medical Corporation, Doha, Qatar.
³ Community Medicine Department, Hamad Medical Corporation, Doha, Qatar.
⁴ Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.

Abstract

The Brugada syndrome is an uncommon inherited condition associated with increased risk of ventricular tachyarrhythmias and sudden cardiac death. Different triggers including fever are well known to precipitate the Brugada pattern on electrocardiogram. We report a patient who presents with syncope, two days after the first dose of the BNT162b2 vaccine due to fever-related unmasking of Brugada syndrome.

Keywords: BNT162b2; Brugada; COVID-19; Coronavirus; Syncope; Vaccine.

Publication types

Case Reports